INOV8 R3ta Plus 1

INOV8 R3ta Plus 1 is a next-generation hybrid injectable pen combining the powerful weight loss and metabolic control of Retatrutide with the mitochondrial support and performance enhancement of MOTS-c. Designed for both body composition and longevity, R3ta Plus 1 represents the cutting edge of metabolic medicine.

Each 2.6 mL Pen (240 clicks) contains:

• Retatrutide: 30 mg
• MOTS-c: 50 mg

Per Click (≈0.0108 mL):

• Retatrutide ~0.125 mg
• MOTS-c ~0.208 mg

Directions for Use

• Frequency: Twice weekly (approx. every 3–4 days).
• Best Time: Morning or early afternoon → maximizes appetite control, insulin sensitivity, and daytime energy.
• Method: Subcutaneous injection (rotate injection sites, sterile needles only).
• Storage: Refrigerate (2–8 °C), protect from light.

Suggested 12-Week Protocol:

Weeks	Dose (Clicks)	Retatrutide	MOTS-c	Focus
1–2	10 clicks	1.25 mg	2.08 mg	Gentle start, appetite reset
3–4	14 clicks	1.75 mg	2.9 mg	Metabolic activation
5–8	20 clicks	2.5 mg	4.2 mg	Weight loss acceleration, insulin support
9–12	28 clicks	3.5 mg	5.8 mg	Peak effect: fat loss, mitochondrial energy

Pen Longevity

Clicks per Dose	Doses per Pen (240 clicks)	Weeks of Supply (2x Weekly)
10 clicks	24 doses	12 weeks
14 clicks	17 doses	~8½ weeks
20 clicks	12 doses	6 weeks
28 clicks	8 doses	4 weeks

Compound Data

Ingredient	Function	Benefits
Retatrutide	Triple-agonist (GLP-1, GIP, Glucagon receptors)	Potent appetite suppression, enhanced fat loss, improved glycemic control
MOTS-c	Mitochondrial peptide regulating AMPK pathway	Increases insulin sensitivity, enhances endurance, improves fat metabolism, supports cellular resilience

Quality Assurance

• Produced in a GMP-certified sterile facility with rigorous quality control.
• Raw peptides validated by HPLC and MS testing for purity.
• Batch-coded pens with traceability and expiry date.
• Cold-chain shipping ensures MOTS-c and Retatrutide remain stable.
• Supplied with sterile, medical-grade needles.

Safety & Warnings

• Adult use only (18+).
• Not suitable during pregnancy, for individuals with active cancers, or severe liver/kidney impairment.
• Monitor: blood glucose, lipids, IGF-1, liver/kidney markers.
• Mild GI side effects possible in early weeks (common with GLP-1 agonists).
• Cycle in 12-week blocks with 2–4 week breaks before repeating or rotating therapies.

Additional Reading

• NEJM: Clinical trials of Retatrutide in obesity and diabetes management.
• Nature Metabolism: Role of MOTS-c in metabolic health and mitochondrial regulation.
• Cell Reports: AMPK activation and MOTS-c in skeletal muscle adaptation.
• Lancet Diabetes & Endocrinology: Combination incretin therapies and long-term weight loss.

R3ta Plus 1 is more than a weight loss tool — it’s a hybrid solution uniting metabolic control and cellular energy.

Buy Now!